Vivek Subbiah

Trials

Studies that name Vivek Subbiah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:00 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06400225 · Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

  National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
• N/A
  NCT04504604 · TCF-001 TRACK (Target Rare Cancer Knowledge) Study

  TargetCancer Foundation · recruiting · Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site · principal investigator
• N/A
  NCT04028479 · The Registry of Oncology Outcomes Associated With Testing and Treatment

  Taproot Health · completed · Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer · principal investigator
• Ph1
  NCT03430882 · Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

  M.D. Anderson Cancer Center · completed · Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
• Ph1
  NCT03188328 · Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

  Alfasigma S.p.A. · terminated · Inoperable Solid Tumors or Lymphomas · principal investigator
• Ph1
  NCT03017833 · Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

  M.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
• Ph1/Ph2
  NCT02842125 · Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

  MultiVir, Inc. · terminated · Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer · principal investigator
• Ph1
  NCT02095054 · Regorafenib and Cetuximab in Patients With Advanced Malignancy

  M.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
• Ph1
  NCT01957735 · BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

  BPGbio · completed · Metastatic Cancer, Cancer, Solid Tumor · principal investigator
• Ph1/Ph2
  NCT01833520 · Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

  M.D. Anderson Cancer Center · completed · Sarcoma · principal investigator
• Ph1
  NCT01596140 · Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

  M.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumor · principal investigator
• Ph2
  NCT00094445 · Trial of Curcumin in Advanced Pancreatic Cancer

  M.D. Anderson Cancer Center · completed · Pancreatic Neoplasms, Adenocarcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2015 to 2026
  Named on NCT06400225
• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026
  Named on NCT03017833
• R21CA104337
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT00094445